Malignant Hyperthermia: Management without DANTROLENE

Management without dantrolene

  • Sobia Manzoor skims,soura
  • Syed Amer Zahoor Department of Anaesthesiology & Critical Care SKIMS
  • Jan Mohammad Rather skims,soura
DOI: https://doi.org/10.33883/jms.v21i1.332
Keywords: Dantrolene, Malignant hyperthermia, Succinyl choline

Abstract

Malignant Hyperthermia(MH) is a hypermetabolic syndrome which is quite rare in India.  Inhalational anesthetics and succinyl choline have been reported as potent triggering agents of MH. Dantrolene remains the gold standard for treating this life-threatening syndrome.

We encountered a case of malignant hyperthermia in a 34-year-old male undergoing ventricular septal defect closure under general anesthesia. We successfully managed our patient by timely recognition of this syndrome and by administering prompt, effective symptomatic treatment and without dantrolene which was not available in our hospital. JMS 2018;21(1):40-43

 

Downloads

Download data is not yet available.

Author Biographies

Sobia Manzoor, skims,soura

M.D., Senior Resident

Syed Amer Zahoor, Department of Anaesthesiology & Critical Care SKIMS

M.D., Professor

Jan Mohammad Rather, skims,soura

M.S., Senior Resident

Published
2018-12-01
How to Cite
1.
Manzoor S, Zahoor S, Rather J. Malignant Hyperthermia: Management without DANTROLENE. jms [Internet]. 2018Dec.1 [cited 2026Oct.28];21(1):40-3. Available from: http://jmsskims.org/index.php/jms/article/view/332
Issue
Vol 21 No 1 (2018): January June
Section
Case Reports